PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 20260 citationsOpen Access

Quantitative Degradation Rate Assessment of bioPROTACs Based on Peptide Degrons, E3 Domains, Adapters and Conjugated Small Molecules

View Full Paper
DVDavid VukovicDWDorothea WinkelvoßAUAnto Udovcic

Key Points

  • To compare the degradation efficacy of various recruitment domains in bioPROTACs to optimize their performance.
  • Utilized eGFP as a degradation target with an eGFP-binding DARPin as an adapter.
  • Employed microinjection and live-cell microscopy for real-time degradation assessment.
  • Examined nine degron peptides, three E3 ligase domains, and two small-molecule binder series.
  • bioPROTACs with E3 or adapter domains and small molecules exhibited the highest degradation rates.
  • Most degron peptides demonstrated comparatively low efficacy.
  • Linker position and coupling site placement significantly affected performance for specific ligands.

Abstract

Protein-based bispecific degraders, known as bioPROTACs, have emerged as powerful tools for targeted protein degradation through the ubiquitin-proteasome system (UPS). However, the relative efficacy of various recruitment domains within these degraders remains poorly understood. To address this knowledge gap, we conducted a comprehensive comparison of recruitment domains in bioPROTACs, utilizing eGFP as a proof-of-principle degradation target and an eGFP-binding DARPin with known structure as an adapter. Our innovative approach combined microinjection and live-cell microscopy, enabling a detailed assessment of directly measured degradation rates as a single-cell kinetic readout, unaffected by uptake or biosynthesis rates of the degrader, and across the different chemical classes. We examined nine degron peptides, three E3 ligase domains or adapters, and two series of small-molecule binders, linked in various geometries. Our results revealed that bioPROTACs based on E3 or adapter protein domains and small molecules generally exhibited the highest degradation rates, while most degron peptides showed comparatively low efficacy. Notably, for VHL-ligand-1 and thalidomide, the placement of the coupling site and linker position significantly influenced performance. This study provides crucial insights into the design and optimization of bioPROTACs, paving the way for the development of more effective degraders for specific applications. Our findings contribute to the growing field of targeted protein degradation and offer valuable guidance for researchers seeking to enhance the efficacy of bioPROTAC-based therapeutic approaches.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Vukovic et al. (2026) studied this question.

synapsesocial.com/papers/6980fc37c1c9540dea80df96https://doi.org/10.5167/uzh-283131
Ask AI
Helpful
Bookmark
Share
View Full Paper